Protherics PLC - Director/PDMR Shareholding
28 Oktober 2008 - 7:43PM
Marketwired
Protherics PLC
Notification of Directors' Interests
London, UK; Brentwood, TN, US: 28 October 2008 - Protherics PLC
("Protherics" or the "Company"), the international
biopharmaceutical
company focused on critical care and cancer, in accordance with
the FSA
Disclosure and Transparency Rules, announces that, on 23 October
2008, pursuant to the conversion of all outstanding six per cent.
unsecured convertible loan notes 2010 of Protherics, the following
ordinary shares (the "Shares") were allotted to Directors of
Protherics
PLC:
Director Nominal Value of Loan Shares allotted share
%
Notes converted capital
issued
Andrew Heath GBP24,242 96,968
0.028%
Stuart Wallis GBP60,606 242,424
0.069%In
accordance with the Loan Note Instrument, the Shares were
allotted
at a price of 25 pence per share.
Following the above allotment of Shares, their interests in the
ordinary share capital of the Company are as follows:
No. Shares % issued share capital
Andrew Heath 516,778 0.148%
Stuart Wallis 809,113 0.231%
/ Ends /
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contacts: RNS Customer Services 0044-207797-4400 Email Contact
http://www.rns.com
Protherics (NASDAQ:PTIL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Protherics (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Protherics PLC News-Artikel